Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by uniQure Inc.
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
August 15, 2024
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
August 01, 2024
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
July 23, 2024
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
July 09, 2024
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
July 01, 2024
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
June 03, 2024
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 07, 2024
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
February 28, 2024
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
December 19, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease
November 29, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 07, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 24, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
October 05, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy
September 05, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 01, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs
June 26, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
June 21, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
June 20, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
ASX:CSL
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
May 15, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure to Participate in Multiple Upcoming Industry Conferences in March
March 02, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress
February 27, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
QURE
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
February 23, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
ASX
QURE
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
February 21, 2023
From
uniQure Inc.
Via
GlobeNewswire
Tickers
ASX
QURE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.